- Home
- MRNA
MRNA
Moderna Inc.
as 10-17-2024 4:00pm EST
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 34.6B | IPO Year: | 2018 |
| Target Price: | $95.93 | AVG Volume (30 days): | 5.0M |
| Analyst Decision: | Hold | Number of Analysts: | 16 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -15.36 | EPS Growth: | N/A |
| 52 Week Low/High: | $54.82 - $170.47 | Next Earning Date: | 11-07-2024 |
| Revenue: | $5,050,000,000 | Revenue Growth: | -52.60% |
| Revenue Growth (this year): | -51.68% | Revenue Growth (next year): | 5.29% |
Stock Insider Trading Activity of Moderna Inc. (MRNA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Klinger Shannon Thyme | MRNA | Chief Legal Officer | Sep 6 '24 | Sell | $73.57 | 551 | $40,538.78 | 18,154 | |
| Klinger Shannon Thyme | MRNA | Chief Legal Officer | Aug 30 '24 | Sell | $76.99 | 114 | $8,776.75 | 18,154 | |
| Hoge Stephen | MRNA | President | Aug 30 '24 | Sell | $76.99 | 318 | $24,482.50 | 1,443,002 | |
| Mock James M | MRNA | Chief Financial Officer | Aug 28 '24 | Sell | $78.03 | 162 | $12,640.21 | 8,767 | |
| Klinger Shannon Thyme | MRNA | Chief Legal Officer | Aug 28 '24 | Sell | $78.03 | 162 | $12,640.21 | 18,154 | |
| Hoge Stephen | MRNA | President | Aug 28 '24 | Sell | $78.03 | 300 | $23,407.80 | 1,443,002 | |
| Mock James M | MRNA | Chief Financial Officer | Aug 27 '24 | Sell | $79.39 | 1,321 | $104,880.66 | 8,767 | |
| Klinger Shannon Thyme | MRNA | Chief Legal Officer | Aug 27 '24 | Sell | $79.39 | 1,319 | $104,721.87 | 18,154 | |
| Hoge Stephen | MRNA | President | Aug 9 '24 | Sell | $84.10 | 254 | $21,362.59 | 1,443,002 | |
| AFEYAN NOUBAR | MRNA | Director | Jul 31 '24 | Sell | $120.33 | 15,000 | $1,799,442.80 | 2,224,015 |
Latest Moderna Inc. News
MRNA Breaking Stock News: Dive into MRNA Ticker-Specific Updates for Smart Investing
ACCESSWIRE
16 hours ago
Moderna to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024
Insider Monkey
a day ago
Is Moderna, Inc. (MRNA) the Most Promising Biotech Stock According to Hedge Funds?
Zacks
2 days ago
Moderna Stock Falls 20% in a Month: Time to Sell or Hold?
BioPharma Dive
2 days ago
GSK claims Moderna infringed mRNA vaccine patents
Barrons.com
2 days ago
Use This ‘Double Up’ Options Strategy to Cut Your Tax Bill
MT Newswires
2 days ago
Update: GSK Sues Moderna for Patent Infringement Related to COVID Vaccines
MT Newswires
2 days ago
GSK Sues Moderna for Patent Infringement Related to COVID Vaccines
Reuters
3 days ago
GSK sues Moderna for US patent infringement over COVID, RSV vaccines
Compare MRNA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MRNA Moderna Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.